FindTrial
Sign In

To examine how useful PD-L1 (Programmed Cell Death Ligand 1) is as a marker for understanding tumor behavior in histopathological confirmed cases of oral squamous cell carcinoma (OSCC) patients and using anti-PD-L1 antibodies as effective immunotherapy for OSCC patients.

To study the utility of PDL1(Programmed Cell Death Ligand One) expression as a immunohistochemical marker for assessing tumor behavior in comparison to histopathological grading and TNM staging in oral squamous cell carcinoma patients. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/01/079571
Enrollment
94
Registered
2025-01-27
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx

Interventions

Intervention1: NIL: NIL

Sponsors

Datta Meghe Institute of Higher Education and Research (DMIHER)
Lead Sponsor
Indian council for Medical Research
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1)Histo pathologically confirmed case of oral squamous cell carcinoma 2)All operated cases of Oral squamous cell carcinoma 3)All patients with oral squamous cell carcinoma arising Denovo 4)All cases with Composite resection of lesion, suitable Modified radical neck dissection (MRND), reconstruction with suitable flap`

Exclusion criteria

Exclusion criteria: 1)All cases of malignancy other than oral squamous cell carcinoma. 2)All cases of non - neoplastic lesions of oral cavity 3)Cases of recurrence. 4)Cases with previous history of chemotherapy and radiotherapy

Design outcomes

Primary

MeasureTime frame
Conclusions will be drawn from the results obtained from IHC study using PDL1 for detecting its expression and correlate with the molecular subtypes of the oral squamous cell carcinoma.Timepoint: 2 years—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactShailly Tiwari

Datta Meghe Institute of Higher Education and Research(DMIHER)

samarth21174@gmail.com8830267710

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026